Literature DB >> 8931286

Measurement of oxygen concentration in delivery systems used for hyperbaric oxygen therapy.

R N Stephenson1, I Mackenzie, S J Watt, J A Ross.   

Abstract

Efficient delivery of oxygen is important during hyperbaric oxygen therapy. We compared two systems in common use, and developed a method to ensure that O2 delivery was adequate during treatment. The systems were a demand valve system with an oral-nasal mask, and a continuously ventilated hood. Five groups were studied over two different time periods, and a further trial was undertaken to examine exhaled O2 levels. The results showed that an acceptable Fio2 could be reliably achieved only with the continuously ventilated hood system or when trained staff supervised their colleagues using the demand system. Inasmuch as the oral-nasal mask system is the standard equipment for the North Sea diving industry, this work shows the importance of ensuring that the correct dose of O2 is delivered. The study indicates, however, that identification of the problem does not always allow a complete solution, and that a hood-based system is more reliable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931286

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  3 in total

1.  The myopic shift associated with hyperbaric oxygen administration is reduced when using a mask delivery system compared to a hood - a randomised controlled trial.

Authors:  Michael H Bennett; Cheng Fb Hui; Hooi G See; Kwan L Au-Yeung; Christopher Tan; Stephanie Watson
Journal:  Diving Hyperb Med       Date:  2019-12-20       Impact factor: 0.887

2.  Decompressing rescue personnel during Australian submarine rescue operations.

Authors:  Michael P Reid; Andrew Fock; David J Doolette
Journal:  Diving Hyperb Med       Date:  2017-09       Impact factor: 0.887

Review 3.  Monoplace chamber treatment of decompression illness: Review and commentary.

Authors:  Richard Clarke
Journal:  Diving Hyperb Med       Date:  2020-09-30       Impact factor: 0.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.